P1

1
Questions and Answers
2
PDR as Reason for Hemorrhage Any Laser Therapy
Prior to Vitrectomy
Vitrase Integrated Phase III Data
3
Recurrent Vitreous Hemorrhage All Incidents
(Severity)
Vit-02
4
Reduction in Hemorrhage Density by 3 Months
(Screening Lens Status)
Vitrase Integrated Phase III Data
5
Achieved BCVA of LogMAR 1.0 or Better Cumulative
Percentages
Vitrase Integrated Phase III Data
6
Achieved BCVA of LogMAR 1.0 or Better Cumulative
Percentages
Vit 02 North America
7
Achieved BCVA of LogMAR 1.0 or Better Cumulative
Percentages
Vit 03 Ex North America
8
Retinal Detachment (Type of Detachment)
Vit-02
9
Retinal Detachment (Type of Detachment)
Vit-03
10
Retinal Detachment Prior to Vitrectomy(Time to
Diagnosis)
Vitrase Integrated Phase III Data
11
Breslow-Day P-Values55 IU vs Saline
12
Hypopyon Duration
Vitrase Integrated Phase III Data
13
Iritis by Reduction in Hemorrhage Density
Vitrase Integrated Phase III Data
14
Reduction in Hemorrhage Densityby Iritis
Vitrase Integrated Phase III Data
15
Improvement in BCVALife Table Analysis
Vitrase Integrated Phase III Data
16
Retinal Detachment After and Prior to Vitrectomy
Vitrase Integrated Phase III Data
17
Retinal Detachment After and Prior to Vitrectomy
Vit 02 North America
18
Retinal Detachment After and Prior to Vitrectomy
Vit 03 Ex North America
19
Retinal Detachment(Time to Diagnosis)
Vitrase Integrated Phase III Data
20
Retinal Detachment(Time to Diagnosis)
Vit 02 North America
21
Retinal Detachment(Time to Diagnosis)
Vit 03 Ex North America